HER2 Lung Cancer Resistance and Emerging Research With Dr. Kyle Concannon | Ep. 3 of 3

In Part 3 of our HER2-driven lung cancer series, Leah Phillips and thoracic medical oncologist Dr. Kyle Concannon (UC Health, University of Colorado) tackle the harder questions. They get into what resistance actually means, the difference between on-target and off-target resistance, why a cancer can sometimes transform into a different type entirely, and the emerging research and combination approaches being studied for HER2 lung cancer patients.This is a conversation many patients will eventually need to have. The research is moving fast and there is real reason for hope.Thanks to Boehringer Ingelheim for supporting this series. YLCI retains full editorial control.This content is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.